Oral zinc supplementation in the treatment of HIV-infected children. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Oral zinc supplementation in the treatment of HIV-infected children.

Pediatr AIDS HIV Infect. 1994 Dec;5(6):357-60. Unique Identifier : AIDSLINE AIDS/95368372
Reich EN; Church JA; Division of Allery-Clinical Immunology, Childrens Hospital, Los; Angeles, California, USA.

Abstract: Primary zinc (Zn) deficiency has been reported to cause immune dysfunction; secondary Zn deficiency has been noted in HIV-infected adults; and in vitro studies have suggested that Zn may have antiviral activity. Zn supplementation was studied in HIV-infected children to evaluate selected clinical and laboratory responses. Thirteen clinically stable HIV-infected children (five females, eight males, 1.5-10 years of age, mean 6 years) with CD4+ counts < 500/mm3 were supplemented with oral elemental zinc at 1.8-2.2 mg/kg/day for 3 to 4 weeks. HIV p24 antigen (p24) levels, T-cell subsets, and serum Zn and copper (Cu) levels were measured before and at the end of Zn supplementation. Clinical assessment of appetite, sense of well being, weight change, and days of fever over 38 degrees C was performed at these times. Baseline serum Zn levels were abnormally low in nine (69%) HIV-infected children. After oral elemental Zn supplementation, six had increased their serum Zn level into the normal range. However, only two patients had increased CD4+T-cell numbers and none of the seven patients with positive p24 had decreased p24 levels. Clinical scores improved in only four patients. This study does not demonstrate impressive short-term benefit from oral Zn supplementation in HIV-infected children.
Keywords: Administration, Oral Child Child, Preschool Copper/BLOOD CD4 Lymphocyte Count/DRUG EFFECTS Evaluation Studies Female Human HIV Core Protein p24/BLOOD/DRUG EFFECTS HIV Infections/*DRUG THERAPY/IMMUNOLOGY Infant Male Zinc/ADMINISTRATION & DOSAGE/DEFICIENCY/*THERAPEUTIC USE CLINICAL TRIAL JOURNAL ARTICLE

KWDadministration,oralchildchild,preschoolcopper/bloodcd4lymphocytecount/drugeffectsevaluationstudiesfemalehumanhivcoreproteinp24/blood/drugeffectshivinfections/KWDdrugtherapy/immunologyinfantmalezinc/administration&dosage/deficiency/KWDtherapeuticuseclinicaltrialjournalarticle
951130
M95B0938

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .